Rasagiline for Parkinson’s Disease
The FDA has approved the molecular entity rasagiline (Agilect, Azilect, Teva Pharmaceuticals, Israel) for the treatment of Parkinson’s disease. The drug is a monoamine oxidase type-B inhibitor that blocks the breakdown of dopamine. Dopamine sends information to the parts of the brain that control movement and coordination. Parkinson’s disease is caused by the destruction of [...]
Read User's Comments